Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, ...

From the eye care experts at Bausch and Lomb, LUMIFY works in 1 minute and ... potential side effects associated with other redness relief drops, when used as directed LUMIFY contains no bleach ...

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

Consumer medical giant Bausch + Lomb may be preparing to sell off its eye care business, which would include contact lens manufacturing taking place in Rochester, N.Y. The Financial Times wrote Sept.

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Blackstone, Advent International and TPG are among a long list of private equity firms studying bids for Bausch + Lomb, according to ... in the more profitable eye care business.

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...